Pharmaceutical composition containing a salt-inducible kinase inhibitor compound
A novel compound inhibiting SIK1, SIK2, and SIK3 addresses the ineffectiveness of existing inhibitors by promoting anti-inflammatory responses, providing therapeutic benefits for diseases associated with SIK dysregulation.
JP2026091282APending Publication Date: 2026-06-03TANABE PHARMA CORP
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- TANABE PHARMA CORP
- Filing Date
- 2025-11-21
- Publication Date
- 2026-06-03
AI Technical Summary
Technical Problem
Existing pharmaceutical compounds are ineffective in inhibiting all three isoforms of salt-inducible kinases (SIK1, SIK2, and SIK3), which are crucial for regulating metabolic processes and are dysregulated in various cancers, necessitating the development of a compound that can effectively inhibit all three isoforms.
Method used
A novel compound represented by formula (I) that includes specific substituents and can form pharmaceutically acceptable salts, capable of inhibiting SIK1, SIK2, and SIK3, is developed.
Benefits of technology
The compound effectively inhibits all three SIK isoforms, promoting anti-inflammatory cytokine production and suppressing inflammatory cytokines, offering therapeutic potential for various diseases associated with SIK dysregulation.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2026091282000001 
Figure 2026091282000002 
Figure 2026091282000003
Abstract
The objective is to provide a pharmaceutical composition containing a novel compound that can effectively inhibit all three SIK1, SIK2, and SIK3. [Solution] A pharmaceutical composition containing the compound shown in formula (I) as an active ingredient. TIFF2026091282000419.tif73161
Need to check novelty before this filing date? Find Prior Art